---
title: "NovaBridge Biosciences SVP Clinical Development Xu Cong Claire sells USD 3,991 common shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291987656.md"
description: "NovaBridge Biosciences SVP of Clinical Development, Xu Cong Claire, sold 4,485 common shares on July 6 at $0.89 per share. This transaction reduced her beneficial ownership to 298,101 shares. The sale followed the acquisition of 12,432 shares via an RSU-related transaction on July 4. The information was reported via EDGAR."
datetime: "2026-07-07T23:51:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291987656.md)
  - [en](https://longbridge.com/en/news/291987656.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291987656.md)
generator: "portal-rs"
---

# NovaBridge Biosciences SVP Clinical Development Xu Cong Claire sells USD 3,991 common shares

-   NovaBridge Biosciences SVP, Clinical Development Xu Cong Claire reported a net reduction in ordinary share holdings in early July. \* Sold 4,485 ordinary shares on July 6 at $0.89, cutting beneficial ownership to 298,101 ordinary shares. \* Previously acquired 12,432 ordinary shares on July 4 via an RSU-related transaction. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0002114309-26-000005), on July 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [NBP.US](https://longbridge.com/en/quote/NBP.US.md)

## Related News & Research

- [Novabridge Biosciences Signals Promise Amid Funding Hurdles](https://longbridge.com/en/news/297103095.md)
- [NovaBridge net loss widens to $37.9 million in FY26 first half; R&D expenses more than doubled to $14.3 million](https://longbridge.com/en/news/296478660.md)
- [Valion Bio announces 1-for-25 reverse stock split effective Aug. 31](https://longbridge.com/en/news/297186352.md)
- [Beacon Pointe Advisors LLC Buys Shares of 90,487 Colgate-Palmolive Company $CL](https://longbridge.com/en/news/297394859.md)
- [Kevin Tang reports sale of 18,300 Boundless Bio shares worth $54,351](https://longbridge.com/en/news/297365336.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**